Research on Human Insulin rDNA Safety and Efficacy in Patients With Type 2 Diabetes Mellitus

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 238 participants.

Also called NCT05161741

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 238 participants (enrolled count) (from the registry)
Sponsor
  • Getz Pharma Registry lists this organization as the lead sponsor
Registry
  • NCT NCT05161741
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Pakistan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05161741. Allocation not applicable; no masking; primary purpose treatment. Start 2021-01-01 (actual); primary completion 2022-11-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Research on Human Insulin rDNA Safety and Efficacy in Patients With Type 2 Diabetes Mellitus
Acronym
RISE
Condition
Adverse Drug Event
Condition
Effect of Drug
Condition
Type 2 Diabetes Treated With Insulin
Intervention (Drug)
Insulin
Lead sponsor
Getz Pharma (class: industry)

Record details

Record id
cardio:ct-nct05161741
Content hash
902807792a5dcf1559ee23076b5bcd3805889b83b0e4f85699bd113ca1db9ce8